Biogen (BIIB) option implied volatility into Clinical Trials on Alzheimer's Congress
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall, dragged by Alphabet and megacap tech; focus on Iran
- Oil falls almost 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Spain's ex-transport minister sentenced to 24 years for corruption
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
Biogen (BIIB) Stock Falls on Alzheimer's Drug Trial Death Reports
November 28, 2022 10:05 AM ESTBiogen (NASDAQ: BIIB) shares dipped Monday after a report by Science.org stated that a woman participating in a trial of experimental Alzheimer's treatment lecanemab had recently died from a brain hemorrhage.
According to the report, some researchers linked the brain hemorrhage to the drug. It is said to be the second death thought to be associated with lecanemab,... More
